Latest Period
n/a
Security Snapshot
UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (UNCY) Institutional Ownership
CUSIP: 90466Y103
13F Institutional Holders and Ownership History from Q3 2021 to Q2 2025
Institutions Reporting
Shares (Excl. Options)
Price
$0.75
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- UNCY on Nasdaq
- Shares outstanding
- 18,578,488
- Price per share
- $0.75
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- UNCY - UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share is tracked under CUSIP 90466Y103.
- Latest finished 13F holder period is not available.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 29 to 0 between Q1 2025 and Q2 2025.
- Reported value moved from $34,451,479 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Schedule 13D/G
Open SEC Evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Investment Quick Answers
What is CUSIP 90466Y103?
CUSIP 90466Y103 identifies UNCY - UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 90466Y103:
Significant Owners of UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (UNCY) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 10% | $38,405,889 | 60,961,729 | Vivo Opportunity Fund Holdings, L.P. | 31 Mar 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $8,370,042 | +$1,112,366 | 13,285,781 | +15% | RA Capital Management, L.P. | 31 Mar 2025 |
| GREAT POINT PARTNERS LLC | 10% | $7,228,095 | 11,473,166 | Great Point Partners, LLC | 31 Dec 2024 | |||
| Walleye Capital LLC | 4.8% | $3,150,000 | 5,000,000 | Walleye Capital LLC | 31 Dec 2024 | |||
| Nantahala Capital Partners Limited Partnership | 2.8% | -62% | $1,895,683 | -$3,073,653 | 3,009,021 | -62% | NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 19 Dec 2024 |
| Nantahala Capital Management, LLC | 10% | 0% | $1,391,993 | +$466,046 | 1,855,991 | +50% | Nantahala Capital Management, LLC | 30 Sep 2025 |
Institutional Holders of UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (UNCY) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q2 | 0 | $0 | -$34,451,479 | $0.75 | 0 |
| 2025 Q1 | 59,926,848 | $34,451,479 | -$1,351,595 | $0.57 | 29 |
| 2024 Q4 | 61,700,962 | $49,002,183 | +$12,116,344 | $0.79 | 31 |
| 2024 Q3 | 46,786,564 | $19,084,180 | +$10,632,565 | $0.41 | 28 |
| 2024 Q2 | 18,997,259 | $9,519,281 | -$954,361 | $0.50 | 23 |
| 2024 Q1 | 14,441,576 | $19,929,234 | +$6,691,650 | $1.38 | 21 |
| 2023 Q4 | 13,030,671 | $11,307,131 | -$1,007,258 | $0.87 | 16 |
| 2023 Q3 | 14,192,814 | $12,205,365 | +$11,249,090 | $0.86 | 16 |
| 2023 Q2 | 1,074,486 | $1,375,341 | -$1,380,929 | $1.28 | 15 |
| 2023 Q1 | 1,686,443 | $3,541,351 | +$1,994,377 | $2.10 | 13 |
| 2022 Q4 | 795,253 | $428,290 | -$100,167 | $0.54 | 9 |
| 2022 Q3 | 968,202 | $571,000 | -$128,238 | $0.59 | 11 |
| 2022 Q2 | 1,194,501 | $992,000 | +$8,181 | $0.83 | 14 |
| 2022 Q1 | 1,150,630 | $1,475,000 | +$40,949 | $1.28 | 11 |
| 2021 Q4 | 1,115,406 | $2,298,000 | -$90,197 | $2.06 | 9 |
| 2021 Q3 | 1,065,645 | $3,015,000 | +$3,015,000 | $2.83 | 9 |